Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment Strategy for Rifampin-Susceptible Tuberculosis.
Paton NI, Cousins C, Suresh C, Burhan E, Chew KL, Dalay VB, Lu Q, Kusmiati T, Balanag VM, Lee SL, Ruslami R, Pokharkar Y, Djaharuddin I, Sugiri JJR, Veto RS, Sekaggya-Wiltshire C, Avihingsanon A, Sarin R, Papineni P, Nunn AJ, Crook AM; TRUNCATE-TB Trial Team. Paton NI, et al. Among authors: balanag vm. N Engl J Med. 2023 Mar 9;388(10):873-887. doi: 10.1056/NEJMoa2212537. Epub 2023 Feb 20. N Engl J Med. 2023. PMID: 36808186 Clinical Trial.
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB.
Tweed CD, Wills GH, Crook AM, Amukoye E, Balanag V, Ban AYL, Bateson ALC, Betteridge MC, Brumskine W, Caoili J, Chaisson RE, Cevik M, Conradie F, Dawson R, Del Parigi A, Diacon A, Everitt DE, Fabiane SM, Hunt R, Ismail AI, Lalloo U, Lombard L, Louw C, Malahleha M, McHugh TD, Mendel CM, Mhimbira F, Moodliar RN, Nduba V, Nunn AJ, Sabi I, Sebe MA, Selepe RAP, Staples S, Swindells S, van Niekerk CH, Variava E, Spigelman M, Gillespie SH. Tweed CD, et al. Int J Tuberc Lung Dis. 2021 Apr 1;25(4):305-314. doi: 10.5588/ijtld.20.0513. Int J Tuberc Lung Dis. 2021. PMID: 33762075 Free PMC article. Clinical Trial.
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
Cross GB, Sari IP, Kityo C, Lu Q, Pokharkar Y, Moorakonda RB, Thi HN, Do Q, Dalay VB, Gutierrez E, Balanag VM, Castillo RJ, Mugerwa H, Fanusi F, Kwan P, Chew KL, Paton NI; ROSETTA trial team. Cross GB, et al. Among authors: balanag vm. Lancet Infect Dis. 2023 Jul;23(7):847-855. doi: 10.1016/S1473-3099(23)00067-1. Epub 2023 Mar 23. Lancet Infect Dis. 2023. PMID: 36966799 Clinical Trial.
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R. von Groote-Bidlingmaier F, et al. Lancet Respir Med. 2019 Mar;7(3):249-259. doi: 10.1016/S2213-2600(18)30426-0. Epub 2019 Jan 7. Lancet Respir Med. 2019. PMID: 30630778 Clinical Trial.
Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty--a BOLD analysis.
Burney P, Jithoo A, Kato B, Janson C, Mannino D, Nizankowska-Mogilnicka E, Studnicka M, Tan W, Bateman E, Koçabas A, Vollmer WM, Gislason T, Marks G, Koul PA, Harrabi I, Gnatiuc L, Buist S; Burden of Obstructive Lung Disease (BOLD) Study. Burney P, et al. Thorax. 2014 May;69(5):465-73. doi: 10.1136/thoraxjnl-2013-204460. Epub 2013 Dec 18. Thorax. 2014. PMID: 24353008 Free PMC article.
Burden of obstructive lung disease in a rural setting in the Philippines.
Idolor LF, DE Guia TS, Francisco NA, Roa CC, Ayuyao FG, Tady CZ, Tan DT, Banal-Yang S, Balanag VM Jr, Reyes MT, Dantes RB. Idolor LF, et al. Among authors: balanag vm jr. Respirology. 2011 Oct;16(7):1111-8. doi: 10.1111/j.1440-1843.2011.02027.x. Respirology. 2011. PMID: 21801277
Prevalence of chronic cough, its risk factors and population attributable risk in the Burden of Obstructive Lung Disease (BOLD) study: a multinational cross-sectional study.
Abozid H, Patel J, Burney P, Hartl S, Breyer-Kohansal R, Mortimer K, Nafees AA, Al Ghobain M, Welte T, Harrabi I, Denguezli M, Loh LC, Rashid A, Gislason T, Barbara C, Cardoso J, Rodrigues F, Seemungal T, Obaseki D, Juvekar S, Paraguas SN, Tan WC, Franssen FME, Mejza F, Mannino D, Janson C, Cherkaski HH, Anand MP, Hafizi H, Buist S, Koul PA, El Sony A, Breyer MK, Burghuber OC, Wouters EFM, Amaral AFS; BOLD Collaborative Research Group. Abozid H, et al. EClinicalMedicine. 2024 Jan 21;68:102423. doi: 10.1016/j.eclinm.2024.102423. eCollection 2024 Feb. EClinicalMedicine. 2024. PMID: 38268532 Free PMC article.
Cohort Profile: Burden of Obstructive Lung Disease (BOLD) study.
Amaral AFS, Potts J, Knox-Brown B, Bagkeris E, Harrabi I, Cherkaski HH, Agarwal D, Juvekar S, Anand MP, Gislason T, Nafees AA, Mortimer K, Janson C, Loh LC, Paraguas SN, Denguezli M, Al Ghobain M, Mannino D, Njoroge MW, Devereux G, Seemungal T, Barbara C, Kocabaş A, Ahmed R, Aquart-Stewart A, Studnicka M, Welte T, Tan WC, van Zyl-Smit RN, Koul P, Garcia-Larsen V, Minelli C, Buist AS, Burney P; BOLD Study Collaborative Network. Amaral AFS, et al. Int J Epidemiol. 2023 Dec 25;52(6):e364-e373. doi: 10.1093/ije/dyad146. Int J Epidemiol. 2023. PMID: 37862437 Free PMC article. No abstract available.
19 results